Inspira Technologies OXY B.H.N. Ltd. said it deployed and began a structured commercial evaluation of its FDA-cleared INSPIRA ART100 system at an additional U.S. academic medical center in New York State ranked among the state’s top 10 hospitals in Newsweek’s 2025 list. The company said the system has been integrated into the center’s clinical workflow to support protocol development and assess potential broader adoption.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inspira Technologies OXY BHN Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001185185-26-000603), on February 18, 2026, and is solely responsible for the information contained therein.